866-945-0263 | enquiries@arrowheadpublishers.com

Press Releases

September 15, 2012

Biopharma Leaders to Discuss Growing Importance of Drug Repositioning at the 2nd Annual Drug Repositioning and Indications Discovery Conference

The 2nd Annual Drug Repositioning and Indications Discovery Conference is being held on October 23-24, 2012 in San Francisco, CA. This conference will feature a variety of speakers from academia, industry, non-profits and government.

Their perspectives will provide insight into the field of drug repositioning and the challenges and successes in getting a repositioned drug to the marketplace.  Building on last year’s conference, the 2nd Annual Drug Repositioning and Indications Discovery Conference will cover what has changed in the last year and what continues to drive interest in drug repositioning.

Since the development of new drugs can be time consuming  and expensive, drug repositioning has emerged as a potentially cost-effective and quicker alternative to provide new drugs for pharmaceutical companies’ waning pipelines.  With new technologies and approaches, drug repositioning has become more streamlined and less accidental than it was in the past.  By using a more systematic approach, existing compounds are being tested for both common and neglected diseases faster and with more success.
Speakers and panelists will focus on the following key themes:

  • Market potential of drug repositioning
  • Regulatory issues/timelines and legal frameworks for drug repositioning
  • Drug Repositioning for neglected diseases
  • Computational approaches to drug repositioning
  • Technical innovations & challenges of drug repositioning

Dr. Aris Persidis, President and Co-Founder, Biovista Inc. will discuss using systematic drug repositioning to map drugs and diseases against each other.  He will provide case studies in both rare and mainstream diseases, including multiple sclerosis and Friedreich’s ataxia.

Dr. Barry Bunin, CEO and President, Collaborative Drug Discovery, will chair an exciting panel session entitled A New Era for Drug Repositioning: How Successes and Partnerships are Changing the Drug Development Process.  Panel members include Dr. Christine Colvis, Program Officer, National Institutes of Health, National Center for Advancing Translational Sciences (NCATS), Dr. David Cavalla, Founder, Numedicus Ltd., and Dr. Christopher Lipinski, Scientific Advisor, Melior Discovery.

Sasha K. Richardson, Vice President, GfK Bridgehead will share insight into pricing, reimbursement, access challenges and opportunities for repositioning therapies from both an EU and US payer perspective.  Her presentation will be a mix of historic pitfalls/successes and forward thinking strategies to help navigate the cost constrained environment for reimbursing repositioned therapies.

Numerous other speakers will be participating.  Please visit www.drugrepositioningconference.com to view the full agenda and information on how to register to attend.

Contact Us

PO Box 96
Chanhassen, MN 55317 USA
866-945-0263
www.arrowheadpublishers.com
enquiries@arrowheadpublishers.com

Speaker Opportunities

If you are interested in speaking at one of Arrowhead's conferences or would like to suggest a conference theme for which you have particular expertise, we'd like to hear from you.

Sponsor/Exhibitor Opportunities

Arrowhead sponsorship and exhibitor levels are designed to give your organization the highest level of exposure and opportunity to market products and branding in an environment that is targeted toward facilitating professional networking. We can also build tailor-made packages that will meet your organization's marketing budget and goals. Arrowhead sponsorships are proven to help grow businesses through direct and targeted exposure to industry leaders and decision makers. To gain critical industry exposure via our sponsorship and exhibiting opportunities, please contact us.